Glycominds, LLC specializes in non-invasive diagnostic solutions for gastrointestinal diseases, particularly focusing on conditions such as Crohn's Disease and Inflammatory Bowel Diseases (IBD). The company offers a series of CE MARK IVD kits known as the IBDX® panel, which aids physicians in identifying patients with Crohn's Disease and assessing their risk for bowel damage and the need for surgery. These blood tests are designed to differentiate between IBD and non-IBD, as well as between Crohn's Disease and Ulcerative Colitis, boasting high sensitivity and specificity rates based on extensive clinical studies involving over 7,500 patient samples from various countries. The IBDX kits are user-friendly, featuring quick incubation times and ready-to-use reagents, which enhance their practicality in clinical settings.

In addition to their diagnostic capabilities, Glycominds employs innovative dry specimen technology, licensed from Kepler Diagnostics, Inc., to facilitate cost-effective and efficient shipping of blood samples. This advancement aligns with the growing trend of home testing, allowing patients to access lab tests conveniently. The company is dedicated to maintaining high standards in quality and regulatory compliance, supported by state-of-the-art research and production facilities. Glycominds aims to expand its reach globally, providing healthcare providers with reliable tools for the diagnosis and management of gastrointestinal diseases.

United States

Glycominds, a commercial stage diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease biomarkers with a distinctive focus on the Inflammatory Bowel Disease (IBD).

Glycominds, LLC

Company Details